Sign In
Buy MYNZ
$0.700
+0 (+0%)
At Close: Jul 31, 2026
Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules
08:00pm, Thursday, 12'th Dec 2024
BERKELEY, Calif. and MAINZ, Germany, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific
02:40pm, Tuesday, 03'rd Dec 2024
Mainz Biomed N.V. MYNZ announced a 1-for-40 reverse stock split, effective Dec. 3.
Mainz Biomed Announces Stock Split
08:45am, Friday, 29'th Nov 2024
BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
08:01am, Monday, 21'st Oct 2024
Revenue increases 4% year over year while loss from operations decreases by 32% Pooled Results of ColoFuture and eAArly DETECT studies published at ASCO showing groundbreaking performance with sensiti
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version
08:01am, Tuesday, 08'th Oct 2024
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version; GANZIMMUN Diagnostics to Feature ColoAlert
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
08:01am, Tuesday, 01'st Oct 2024
BERKELEY, Calif. and MAINZ, Germany, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
08:01am, Wednesday, 18'th Sep 2024
BERKELEY, Calif. and MAINZ, Germany, Sept.
BERKELEY, Calif. and MAINZ, Germany, Sept.
Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
08:01am, Thursday, 25'th Jul 2024
BERKELEY, Calif. and MAINZ, Germany, July 25, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test
03:01am, Tuesday, 09'th Jul 2024
On the basis of its positive clinical studies Mainz Biomed has now defined the final configuration including its novel mRNA biomarkers of the Next Generation Test to be used in pivotal registration st
Mainz Biomed Provides Half Year 2024 Corporate Update
08:01am, Tuesday, 02'nd Jul 2024
BERKELEY, Calif. and MAINZ, Germany, July 02, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
08:01am, Monday, 03'rd Jun 2024
New study data confirmed previous ColoFuture and eAArly DETECT study performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia Result
Mainz Biomed Reports Results of 2024 Annual General Meeting
05:01pm, Friday, 31'st May 2024
BERKELEY, Calif. and MAINZ, Germany, May 31, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
08:01am, Tuesday, 28'th May 2024
Key Findings: 92.3% Sensitivity for Colorectal Cancer, 82.3% for Advanced Precancerous Lesions Poster presentation showing new data on 690 subjects including previously unexamined and unreported sampl
Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial
08:01am, Monday, 20'th May 2024
Mainz Biomed Presented Industry Leading Results: 97% Sensitivity for Colorectal Cancer, 82% for Advanced Precancerous Lesions The eAArly DETECT results demonstrated that within the advanced precancero
